Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing-Reference-Cited by-同舟云学术

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing

Published:2015-02 Issue:2 Volume:87 Page:122-129
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Jurmeister Philipp,Lenze Dido,Berg Erika,Mende Stefanie,Schäper Frank,Kellner Udo,Herbst Hermann,Sers Christine,Budczies Jan,Dietel Manfred,Hummel Michael,von Laffert Maximilian

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

3. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement;Schwab;Lung Cancer,2013

4. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC);Ou;Ann Oncol,2013

5. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib;Bos;Lung Cancer,2013

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer;World Journal of Gastrointestinal Surgery;2024-05-27

2. MET alterations in advanced non-small cell lung cancer;Current Problems in Cancer;2024-04

3. Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre;ecancermedicalscience;2024-01-15

4. Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples;Lung Cancer;2023-07

5. State of the Art of Pathologic and Molecular Testing;Hematology/Oncology Clinics of North America;2023-06